Bildkälla: Stockfoto

Idogen: Q1 Report Comment - Redeye

Redeye leaves a comment on Idogen following the report for the first quarter of 2021, which did not include any significant surprises. We reiterate our Base case of SEK 5 per share.

Redeye leaves a comment on Idogen following the report for the first quarter of 2021, which did not include any significant surprises. We reiterate our Base case of SEK 5 per share.
Börsvärldens nyhetsbrev
ANNONSER